CINCINNATI--(BUSINESS WIRE)--Sep. 24, 2018--
Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that Chief Executive Officer, Stephen Hoffman, M.D.,
Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare
Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New
York, NY. Dr. Hoffman will provide a corporate overview and business
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB-9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information, please
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005069/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.